Researchers published a study in the American Chemical Society Journal Applied Material Interfaces which revealed that as the BA.5 omicron variant is spreading, the health professionals are becoming more vigilant and preparing for a future in which COVID-19 variations originate, spike, and wane similarly to seasonal flu.

To help with this problem, they are developing a novel biosensor that might be quick and effective to pass future COVID-19 testing specifications. They employed a fast analysis called high-throughput testing which is more sensitive, quick, effective, and accurate.

According to experts, the recently created COVID-19 test can currently analyze samples from 96 persons in less than 3 hours and performs best with 10 microliters of blood. Additionally, the sensor works with a variety of sample types, including saliva.

Researchers from Indiana University–Purdue University Indianapolis (IUPUI) discovered after conducting a blind test that their biosensor had a 100% accuracy rate and a 90% specificity rate. In other words, the sensor never produced a false negative and only ever returned a false positive in 1 out of 10 samples, which is more important for public safety than the existence of false positives.

Additionally, the research suggests that the sensor can pick up antibodies during the early stages of infection. The sensors accuracy in determining the bodys COVID-19 antibody concentration was demonstrated by its ability to recognize both the spike protein of the virus and the immunoglobin G and IgG, proteins that are produced by the body to combat viruses. To effectively stop COVID-19 in the future, it will be crucial to precisely monitor patients immune capacities. 

(ETHealthWorld, July 23, 2022)